Przejdź do treściPolish version: Osteonekroza biodra — czy komórki szpiku poprawiają wynik dekompresji?
A recent network meta-analysis provides an interesting but not definitive signal: in patients with early or intermediate-stage osteonecrosis of the femoral head, core decompression combined with autologous bone marrow mononuclear cells (BMMNCs) was associated with a lower risk of structural progression on imaging than core decompression alone. The analysis did not, however, show convincingly that this strategy reduces the number of patients who later require total hip arthroplasty.
Why is this study important?
Before collapse of the articular surface, the main objective in femoral head osteonecrosis is to preserve the native joint. Core decompression is intended to create conditions for revascularization and bone remodeling, but its outcomes are variable. Cell-based material derived from bone marrow has therefore been used for years in an attempt to enhance the effect of decompression.
The difficulty is that “cell therapy” covers biologically different products. The new analysis distinguished, among other strategies, autologous bone marrow mononuclear cells (BMMNCs) from bone marrow aspirate concentrate (BMAC). This distinction matters clinically: a result obtained with one preparation should not automatically be generalized to another.
Question and methodology
The authors performed a systematic review and Bayesian network meta-analysis of randomized and quasi-randomized trials. Six databases and trial registries were searched through 6 August 2026. Eligible participants were adults with imaging-confirmed early or intermediate-stage osteonecrosis of the femoral head.
Five strategies were compared: conservative treatment, core decompression (CD) alone, CD with BMMNCs, CD with BMAC, and CD with autologous osteoblastic cells. Two clinically relevant outcomes were assessed: structural/radiographic progression and conversion to total hip arthroplasty.
The network included nine independent studies: seven randomized and two quasi-randomized trials. Eight studies contributed data to each of the two main outcomes.
Results
The clearest signal concerned progression on imaging. Compared with core decompression alone, CD+BMMNC was associated with a significantly lower risk of structural progression (OR 0.02; 95% credible interval 0.000–0.31). The authors rated the certainty of this comparison as moderate using GRADE.
BMMNCs ranked first for both radiographic progression and conversion to arthroplasty. That ranking should not be read as proof of superiority. For later THA, all comparisons involving BMMNCs were directionally favorable, but the credible intervals included no effect. The certainty of evidence for this endpoint was low.
The BMAC-versus-BMMNC comparison was also notable: the estimate suggested a greater risk of progression with BMAC than with BMMNC, but the credible interval was extremely wide (OR 51.77; 95% CrI 1.95–5795.12). Such a wide interval is primarily a marker of sparse data and substantial uncertainty, not a basis for claiming that one preparation is “dozens of times worse” than another.
Clinical interpretation for an orthopaedic surgeon
The most practical message is that cell-based strategies should not be treated as a single intervention. In this analysis, the most consistent signal for structural preservation was seen with BMMNCs used together with core decompression.
This may be relevant when considering joint-preserving treatment in carefully selected patients before femoral head collapse. Radiographic progression, however, is an intermediate outcome. What matters more to patients is whether treatment actually delays or prevents total hip replacement, and the new analysis does not yet establish that.
The biological context of osteonecrosis is also important. Previous material on this site discusses steroid- and alcohol-related mechanisms as well as femoral head osteonecrosis reported after COVID-19. These mechanisms and risk profiles should not be conflated with the efficacy of a particular cell-based adjunct to decompression.
Limitations
- The network was based on only nine independent studies, with individual cell-therapy nodes represented by small numbers of trials.
- Two quasi-randomized studies were included, increasing the risk of bias.
- Cell preparations differed in collection, processing, cell counts, delivery technique and procedural protocol.
- Studies differed in disease stage, follow-up duration and handling of patients with bilateral osteonecrosis.
- The strongest finding concerned progression on imaging rather than the harder clinical endpoint of avoiding total hip arthroplasty.
What could this change in practice—and what does it not prove?
The analysis strengthens the argument for identifying the exact cell product used in both research and clinical practice rather than grouping BMMNCs, BMAC and other preparations under one label. In patients selected for core decompression, it also supports further study of BMMNCs as a specific biological adjunct.
It does not show that every patient with early osteonecrosis should receive cell therapy, that BMMNCs definitely reduce the risk of eventual arthroplasty, or that BMAC is ineffective. Larger multicenter trials are needed, using standardized preparations and procedures, disease-stage stratification and long-term follow-up.
References
- Konarski W, Poboży T, Konarska K, Śliwczyński A, Kotela I, Hordowicz M, Krakowiak J. Osteonecrosis Related to Steroid and Alcohol Use—An Update on Pathogenesis. Healthcare. 2023;11(13):1846. DOI: 10.3390/healthcare11131846.
- Guo Y, Li J, Lu B, et al. Comparative effects of core decompression combined with autologous cell-based strategies on structural outcomes in early-stage osteonecrosis of the femoral head: a systematic review and Bayesian network meta-analysis of randomized and quasi-randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2026. DOI: 10.1186/s13018-026-07218-z.
- Poboży T, Poboży K, Domańska-Poboża J, Konarski W. Impact of COVID-19 on the Development of Femoral Head Avascular Necrosis: A Systematic Review. Medical Sciences. 2026. DOI: 10.3390/medsci14030372.
- Niu Q, Yang X, Liu X, Yang F, He W. Comparative efficacy and safety of core decompression, cell-based therapy, hyperbaric oxygen therapy, extracorporeal shock wave therapy, and combined regimens for osteonecrosis of the femoral head: a network meta-analysis. Front Cell Dev Biol. 2026;14:1876711. DOI: 10.3389/fcell.2026.1876711.
Related resources
For patients: Hip Conditions. For clinicians: Research Updates, Literature and EBM.
Content prepared by: Tomasz Poboży - orthopaedic surgeon.